New hope for tough leukemias: targeted pill BN104 enters human trials
NCT ID NCT06052813
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tests a new drug called BN104 in 66 adults with acute leukemia that has come back or not responded to other treatments. The drug targets specific genetic changes (KMT2A or NPM1 mutations) to try to control the disease. The goal is to find the safest dose and see if it can reduce cancer cells in the bone marrow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALL, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, 215006, China
Conditions
Explore the condition pages connected to this study.